Abstract
Bladder cancer (BC) represents the second most common malignant disease of the urinary tract, and one of the neoplasms that have the highest costs for the Unified Health System. The primary treatment of non-muscle invasive bladder cancer (NMIBC) is based on surgical treatment using transurethral resection, followed by intravesical immunotherapy with Bacillus Calmette-Guérin (BCG), to redu…